Carbimazole, Thiamazole (Methimazole)

Other congenital malformations (Q80-84)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3446
R6433
Andersen (control unexposed, disease free), 2019 Integumentary system (Q80-84) early pregnancy population based cohort retrospective unexposed, disease free Adjustment: No 4.07 [2.24;7.37] C 11/1,574   2,002/1,159,181 2,013 1,574
ref
S3337
R5711
Andersen 2017 (control exposed to PTU), 2017 Integumentary system including breast malformations (Q80–84) early pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.35 [0.03;68.24] C
excluded (control group)
0/162   0/218 0 162
ref
S3335
R5676
Andersen 2017 (control unexposed, disease free), 2017 Integumentary system including breast malformations (Q80–84) early pregnancy population based cohort retrospective unexposed, disease free excluded Adjustment: No 0.74 [0.05;11.95] C
excluded (control group)
0/162   2,826/682,343 2,826 162
ref
S3336
R5690
Andersen 2017 (control unexposed, sick), 2017 Integumentary system including breast malformations (Q80–84) early pregnancy population based cohort retrospective unexposed, sick Adjustment: No 0.50 [0.03;8.67] C 0/162   9/1,551 9 162
ref
Total 2 studies 2.32 [0.38;14.27] 2,022 1,736
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Andersen (control unexposed, disease free), 2019Andersen, 2019 1 4.07[2.24; 7.37]2,0131,57473%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Andersen 2017 (control unexposed, sick), 2017Andersen 2017, 2017 2 0.50[0.03; 8.67]916227%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 50% 2.32[0.38; 14.27]2,0221,7360.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: control unexposed, disease free; 2: control unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.32[0.38; 14.27]2,0221,73650%NAAndersen (control unexposed, disease free), 2019 Andersen 2017 (control unexposed, sick), 2017 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 4.07[2.24; 7.37]2,0131,574 -NAAndersen (control unexposed, disease free), 2019 1 unexposed, sickunexposed, sick 0.50[0.03; 8.67]9162 -NAAndersen 2017 (control unexposed, sick), 2017 1 Tags Adjustment   - No  - No 2.32[0.38; 14.27]2,0221,73650%NAAndersen (control unexposed, disease free), 2019 Andersen 2017 (control unexposed, sick), 2017 2 All studiesAll studies 2.32[0.38; 14.27]2,0221,73650%NAAndersen (control unexposed, disease free), 2019 Andersen 2017 (control unexposed, sick), 2017 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3337, 3335

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 3.06[0.88; 10.62]4,8391,73627%NAAndersen (control unexposed, disease free), 2019 Andersen 2017 (control unexposed, disease free), 2017 2 unexposed, sick controlsunexposed, sick controls 0.50[0.03; 8.67]9162 -NAAndersen 2017 (control unexposed, sick), 2017 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.35[0.03; 68.24]-162 -NAAndersen 2017 (control exposed to PTU), 2017 10.510.01.0